Physician profile
Lanah Han
NPI 1427810290
$4,980.11
in general payments reported to CMS, 2019-2025
41 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,905 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,790 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,790.11 |
| Education | $190.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $334.90 | 2024-2025 | Monjuvi, Pemazyre, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $324.22 | 2024-2025 | Fruzaqla, Iclusig |
| Astellas Pharma US INC | $290.86 | 2024-2025 | Xtandi, Padcev |
| Astrazeneca Pharmaceuticals LP | $281.89 | 2024-2025 | Enhertu, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $263.23 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $247.03 | 2024 | Rybrevant, Imbruvica, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $246.85 | 2024 | |
| Puma Biotechnology, INC. | $234.42 | 2024-2025 | |
| Eisai INC. | $214.07 | 2024 | |
| Gilead Sciences, INC. | $210.77 | 2024 | Trodelvy |
| Sobi, INC | $198.95 | 2024-2025 | |
| Abbvie INC. | $181.65 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $168.87 | 2024-2025 | |
| Daiichi Sankyo INC. | $156.58 | 2024-2025 | Enhertu |
| Amgen INC. | $139.25 | 2024 | Evenity |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $129.18 | 2024-2025 | Cabometyx |
| Beigene USA, INC. | $115.46 | 2024-2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $113.05 | 2024-2025 | Onivyde, Somatuline Depot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.87 | 2024-2025 | Gilotrif |
| Lilly USA, LLC | $92.89 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $83.38 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Emd Serono, INC. | $82.52 | 2024 | |
| Alexion Pharmaceuticals, INC. | $81.09 | 2024 | Ultomiris |
| Genentech USA, INC. | $79.14 | 2024 | Polivy, Phesgo, Itovebi |
| E.R. Squibb & Sons, L.L.C. | $69.48 | 2024 | Opdivo, Opdualag |
| Pharmaessentia USA Corporation | $64.99 | 2024 | Besremi |
| Tempus Ai, INC | $57.81 | 2024 | |
| Karyopharm Therapeutics INC. | $51.96 | 2024-2025 | Xpovio |
| Coherus Oncology, INC. | $46.42 | 2024-2025 | Loqtorzi |
| Stemline Therapeutics INC. | $40.86 | 2024-2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $38.86 | 2025 | |
| Boston Scientific Corporation | $33.89 | 2025 | Avvigo Guidance System |
| Syndax Pharmaceuticals, INC. | $32.99 | 2025 | |
| Adc Therapeutics America, INC. | $31.93 | 2024 | |
| Genzyme Corporation | $28.70 | 2024 | |
| Recordati_rare_diseases_inc. | $25.00 | 2024 | Sylvant |
| Ge Healthcare | $22.32 | 2025 | |
| Deciphera Pharmaceuticals INC. | $21.33 | 2024 | Qinlock |
| Myriad Genetic Laboratories, INC. | $20.36 | 2024 | Myrisk |
| Jazz Pharmaceuticals INC. | $16.04 | 2024 | |
| Janssen Pharmaceuticals, INC | $10.05 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lanah Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.